Ethynylated Heterodinucleotide Cytostatic Drugs for a better Cancer Therapy
Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.
Further Information: PDF
Eberhard Karls Universität Tübingen
Phone: +49 (7071) 29-72639
Contact
Dr. Rolf Hecker
Media Contact
All latest news from the category: Technology Offerings
Newest articles
An Endless Loop: How Some Bacteria Evolve Along With the Seasons
The longest natural metagenome time series ever collected, with microbes, reveals a startling evolutionary pattern on repeat. A Microbial “Groundhog Year” in Lake Mendota Like Bill Murray in the movie…
Witness Groundbreaking Research on Achilles Tendon Recovery
Achilles tendon injuries are common but challenging to monitor during recovery due to the limitations of current imaging techniques. Researchers, led by Associate Professor Zeng Nan from the International Graduate…
Why Prevention Is Better Than Cure—A Novel Approach to Infectious Disease Outbreaks
Researchers have come up with a new way to identify more infectious variants of viruses or bacteria that start spreading in humans – including those causing flu, COVID, whooping cough…